BSX

Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was partly driven by its softer quarterly results and might have investors contemplating their next move. Following the pullback, is now a good time to buy BSX? Find out in our full research report, it’s free. Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE:BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties. Investors interested in Medical Devices & Supplies - Diversified companies should track organic revenue in addition to reported revenue. This metric gives visibility into Boston Scientific’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement. Over the last two years, Boston Scientific’s organic revenue averaged 15.7% year-on-year growth. This performance was impressive and shows it can expand quickly without relying on expensive (and risky) acquisitions. If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills. As you can see below, Boston Scientific’s margin expanded by 9.1 percentage points over the last five years. This is encouraging, and we can see it became a less capital-intensive business because its free cash flow profitability rose more than its operating profitability. Boston Scientific’s free cash flow margin for the trailing 12 months was 16.9%. Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity). Although Boston Scientific has shown solid fundamentals lately, it historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 6.9%, somewhat low compared to the best healthcare companies that consistently pump out 20%+. Boston Scientific’s positive characteristics outweigh the negatives. After the recent drawdown, the stock trades...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Boston Scientific (BSX) has come into focus after promising clinical results coincided with multiple index removals and fresh analyst commentary on its Watchman device franchise and utilization trends. Shares recently moved higher, supported by the clinical update and reports of insider buying, even as analysts highlighted slower Watchman growth and trimmed their expectations. At the same time, Boston Scientific was dropped from several Russell growth benchmarks, including the Russell 1000 Growth, Russell 3000 Growth, Russell Top 200 Growth, Russell 1000 Growth Defensive, and Russell 3000E Growth indices. See our latest analysis for Boston Scientific. At a share price of $44.60, Boston Scientific has seen short term share price momentum fade, with a 30 day share price return down 8.14% and a 90 day share price return down 27.90%. The 1 year total shareholder return is down 57.05%, while the 5 year total shareholder return is up 2.55%, as investors weigh positive clinical data against slower Watchman utilization and the recent removal from several Russell growth indices. If these moves have you reassessing healthcare exposure, it may be a good moment to scan for other opportunities in medical technology and 40 healthcare AI stocks Bulls point to Boston Scientific’s clinical data, revenue and net income growth, and an implied discount to fair value, while bears focus on Watchman concerns and index removals. Which side does the current valuation actually support? Boston Scientific's most followed valuation narrative, according to Bill_S, places fair value at $98.90 per share versus the recent $44.60 close, framing the stock as significantly discounted in that narrative. Read the complete narrative. Want the full story behind that $98.90 fair value for Boston Scientific? The narrative focuses on accelerating earnings power, richer margins, and a future valuation multiple that assumes the Penumbra deal reshapes the company’s revenue mix in a significant way. Result: Fair Value of $98.90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Boston Scientific’s story could shift quickly if Watchman utilization slows further or if the higher debt from the Penumbra deal weighs more heavily on sentime...

Johnson & Johnson's JNJ MedTech division, which includes orthopedics, surgery, cardiovascular, electrophysiology, vision and wound closure products, contributes roughly 36% to the company’s total revenues. J&J is repositioning its MedTech portfolio toward more innovative, faster-growing areas, most notably cardiovascular. With the acquisitions of Shockwave in 2024 and Abiomed in 2022, J&J has become a category leader in four of the largest and highest-growth cardiovascular intervention MedTech markets. J&J is the market leader in heart recovery, circulatory restoration and electrophysiology. J&J’s MedTech business has improved in the last four quarters, driven by the acquired cardiovascular businesses, Abiomed and Shockwave, as well as Surgical Vision and wound closure in Surgery. J&J’s electrophysiology business has also improved significantly in recent quarters, driven by new product launches, including Varipulse and better commercial execution. Investors are likely to have closely monitored the segment's performance in the second quarter to gauge whether these factors continue to drive MedTech’s growth. J&J is scheduled to report second-quarter 2026 results on July 15. In the first quarter of 2026, J&J delivered nearly $8.64 billion in sales in its MedTech segment, reflecting growth of 4.6% on an operational basis. The positive trend is expected to have continued in the second quarter. The MedTech business is expected to have seen strong momentum in three focus areas: Cardiovascular, Surgery and Vision in the second quarter, backed by increased adoption of newly launched products. Orthopedics is likely to have grown at a more moderate pace. However, the company continues to face headwinds in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program, which is a government-driven cost containment effort in China. Sales in China are likely to have been hurt by the impact of the VBP program in the second quarter. On the conference call, investors will also look for updates on the MedTech unit’s outlook for 2026. J&J had earlier said that it expects better growth in the MedTech business in 2026 than 2025 levels, driven by increased adoption of newly launched products across Cardiovascular, Surgery and Vision portfolios. Also, J&J expects continued impacts from VBP issues in China in 2026, mainly in the second half. Anothe...

Headquartered in Marlborough, Massachusetts, Boston Scientific Corporation (BSX) is a global medical technology company that develops and sells devices used in minimally invasive procedures to diagnose and treat a wide range of health conditions. With a market cap of approximately $63.4 billion, the company's products include devices for heart care, such as pacemakers and monitoring systems, as well as tools for treating digestive, urinary, neurological, and vascular disorders, as well as certain cancer-related treatments. CEO Phong Le Bought 11,000 Shares of MicroStrategy Preferred Stock as STRC Hit All-Time Lows S&P Futures Slip With Focus on U.S. ADP Jobs Report and Warsh’s Remarks Analysts at UBS Say Advanced Micro Devices Stock Could Rally to $670 Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. The company is now approaching its fiscal 2026 second-quarter earnings report, set to land on Wednesday, July 29, before the opening bell. Wall Street expects Boston Scientific to post diluted EPS of $0.83, marking a 10.7% gain from the $0.75 the company posted in the same quarter last year. The company also cleared the bar on EPS estimates in each of the last four quarters, which is impressive. Analysts are keeping their eyes further down the runway, too. They forecast full fiscal 2026 diluted EPS of $3.36, which reflects a 9.8% year-over-year gain. The outlook only brightens from there, with full-year 2027 diluted EPS projected to climb to $3.70, representing a 10.1% increase from the prior year. However, the stock chart tells a much bumpier story. Over the last 52 weeks, Boston Scientific’s shares declined 58.9%, falling well behind the broader S&P 500 Index ($SPX), which gained 20.7% over the same stretch. The pain has carried straight into 2026, with BSX stock plummeting nearly 54.8% on a year-to-date (YTD) basis while the benchmark index notched a 9.3% gain. Sector peers tell the same tale. The State Street Health Care Select Sector SPDR ETF (XLV) returned 16.7% over the past 52 weeks and gained 3.1% in 2026, once again leaving Boston Scientific trailing the pack. Still, the stock found a rare bright spot on Wednesday, April 22, when shares surged nearly 9% after the company reported Q1 FY2026 earnings. Revenue climbed 11.6% year over year to $5.20 billion, sailing past analyst e...

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were about flat in l

It has been about a month since the last earnings report for Boston Scientific (BSX). Shares have lost about 13% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Boston Scientific due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Boston Scientific Corporation (BSX) posted first-quarter 2026 adjusted earnings per share (EPS) of 80 cents, up 6.7% from the year-ago figure. The figure matched the Zacks Consensus Estimate. The quarter’s adjustments included certain amortization expenses, litigation-related net charges and restructuring charges, among others. Reported EPS for the first quarter was 90 cents compared with the year-ago quarter’s 45 cents. First-quarter revenues totaled $5.20 billion, up 11.6% year over year on a reported basis and up 9.4% on an operational and organic basis. The top line exceeded the Zacks Consensus Estimate by 0.4%. In the first quarter, revenues rose 10.9% in the United States on a reported basis (same operationally). Reported revenues increased 10.1% in EMEA, or 1.2% on an operational basis, and 14.7% in Asia Pacific, or 12% operationally. Reported revenues increased 19% in Latin America and Canada (up 12% operationally). Boston Scientific recently reorganized its operational structure and aggregated its core businesses into two reportable segments — MedSurg and Cardiovascular. Both these segments generate revenues from the sale of Medical Devices. MedSurg MedSurg revenues in the first quarter totaled $1.70 billion, up 7.8% year over year on a reported basis (up 5.7% on an operational and organic basis). Within this, the Endoscopy unit generated revenues of $736 million, up 6.8% organically and operationally. Urology revenues amounted to $646 million, reflecting organic and operational growth of 0.5%. The Neuromodulation business reported $318 million in revenues, reflecting 15.4% year-over-year organic and operational growth. Cardiovascular The company generates maximum revenues from this segment. Revenues in the first quarter totaled $3.50 billion, up 13.5% (reportedly) and 11.2% (organically and operationally) year over year. The gross margin expanded...

TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing AI concerns. During this period, The Fund (I Share) reported a net loss of 11.75%, lagging behind the Russell 1000 Growth Index return of -9.78%. The Fund considers the market's broadening as a healthy sign and remains confident that the market will eventually recognize the portfolio's intrinsic value. Please review the Fund’s top five holdings to gain insights into their key selections for 2026. In its first-quarter 2026 investor letter, TCW Concentrated Large Cap Growth Fund highlighted Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is a medical technology company that manufactures and markets medical devices for use in various interventional medical specialties. On May 19, 2026, Boston Scientific Corporation (NYSE:BSX) closed at $56.81 per share. One-month return of Boston Scientific Corporation (NYSE:BSX) was -12.42%, and its shares lost 45.71% over the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a market capitalization of $84.44 billion. TCW Concentrated Large Cap Growth Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2026 investor letter: Boston Scientific Corporation (NYSE:BSX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 110 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the fourth quarter, up from 102 in the previous quarter. In the first quarter of 2026, Boston Scientific Corporation (NYSE:BSX) delivered consolidated revenue of $5.203 billion, representing 11.6% year-over-year growth compared to Q1 2025. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, w...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Transitioning to a pure-play drug-eluting biomatrix company by divesting non-core assets to concentrate resources on the high-value NXT-41x platform. Operationalized an automated manufacturing platform designed to deliver precise drug-eluting layers and support gross margins in excess of 80% at scale. Identified a $1.5 billion U.S. market opportunity where 15% to 20% of patients suffer postoperative infections, representing a severe unmet medical need. Leveraging a proven technology framework previously validated by the $88 million sale of the first-generation EluPro business to Boston Scientific. Commercial strategy focuses on extreme market concentration, with only 585 hospitals accounting for 75% of total U.S. procedural volume. NXT-41x is positioned to compete on both clinical outcomes and cost-neutrality, replacing legacy products that lack functional differentiation. Anticipate FDA clearance for the base NXT-41 biologic matrix in the fourth quarter of 2026. Targeting first half of 2027 for FDA clearance of the NXT-41x drug-eluting version, followed by a soft launch in the second half of 2027. Strategic divestitures of SimpliDerm and the Cardiovascular product line are expected to further bolster the balance sheet and management focus. Current cash position of $36.5 million, including escrowed funds, is projected to support all planned regulatory and operational milestones. Future commercial infrastructure will likely utilize a targeted hybrid model of direct reps and 1099s to penetrate high-volume surgical centers. Announced inbound acquisition interest for the Cardiovascular product line, which saw revenue grow from $300,000 to $1 million year-over-year. SimpliDerm divestiture process is active with approximately 38 targets engaged, aimed at maximizing capital for the NXT-41x launch. Net loss increase was primarily driven by non-cash items, specifically the revaluation of warrant liabilities, rather than operational deterioration. Reallocated $2 million from declining litigation costs into R&D and commercial readiness for the NXT-41x program. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management reported that the plastic and reconstructive su...

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation. Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026. Full Year 2026 Financial Outlook and Webcast and Conference Call Information Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X. Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of ri...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Boston Scientific (NYSE:BSX). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That means EPS growth is considered a real positive by most successful long-term investors. Recognition must be given to the that Boston Scientific has grown EPS by 60% per year, over the last three years. That sort of growth rarely ever lasts long, but it is well worth paying attention to when it happens. One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. EBIT margins for Boston Scientific remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 17% to US$21b. That's encouraging news for the company! The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image. See our latest analysis for Boston Scientific In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of Boston Scientific's forecast profits? We would not expect to see insiders owning a large percentage of a US$84b company like Boston Scientific. But thanks to their investment in the company, it's pleasing to see that there are still incentives to align their actions with the shareholders. Notably, they have an enviable stake in the company, w...

MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Mike Mahoney, chairman and chief executive officer, and Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. Additionally, the company will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2026, on Wednesday, July 29, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter 2026 on July 29 prior to the conference call. A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event. About Boston Scientific Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn. CONTACTS: Chanel Hastings Media Relations +1 (508) 382-0288 [email protected] Lauren Tengler Investor Relations +1 (508) 683-4479 [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-participation-in-bernsteins-42nd-annual-strategic-decisions-conference-and-conference-call-discussing-second-quarter-2026-results-302760793.html

Boston Scientific beat expectations in Q1 with organic sales up 9.4%, revenue of $5.203 billion and adjusted EPS of $0.80, while adjusted operating margin was 28%. Management trimmed guidance, cutting full-year organic growth to 6.5–8% and raising full-year adjusted EPS to $3.34–3.41, citing near-term pressure from WATCHMAN, electrophysiology (EP) and Urology (WATCHMAN volumes softened beginning mid‑February). Capital priorities remain strategic tuck‑in M&A and buybacks: the board added $4 billion to reach $5 billion in repurchase authorization with ~$2 billion planned for Q2, the company expects about $4 billion of 2026 free cash flow, and the Penumbra acquisition is still targeted to close in the second half of 2026 pending approvals. Interested in Boston Scientific Corporation? Here are five stocks we like better. Why Boston Scientific's Big Dip Could Be a Bigger Opportunity Boston Scientific (NYSE:BSX) reported first-quarter 2026 results that landed near the top end of management’s prior guidance, while executives reduced their outlook for the remainder of the year citing “unanticipated headwinds” and changing business patterns in several key franchises. Chairman and CEO Mike Mahoney said the company delivered “a solid quarter,” with total company organic sales growth of 9.4% versus a guidance range of 8.5% to 10%. Boston Scientific posted adjusted EPS of $0.80, up 6% year over year and at the high end of its $0.78 to $0.80 range. Adjusted operating margin was 28%. → Credo Stock Flashes Strong Bullish Signal—Upswing Just Starting Beware the Death Cross: 3 Stocks Triggering This Spooky Signal CFO Jon Monson said first-quarter revenue totaled $5.203 billion, representing 11.6% reported growth versus the prior year and including a 220 basis point foreign exchange tailwind ($104 million). Excluding FX, operational and organic revenue growth both came in at 9.4%. On profitability, Monson said adjusted gross margin was 70.5%, down 100 basis points year over year, “primarily driven by tariffs as well as inventory charges related to the discontinuation of our PolarX cryoablation system.” → Allbirds Exits Shoes, Pivots to AI With NewBird Rebrand 3 Healthcare Stocks Using AI to Drive Growth Despite the first-quarter performance, Mahoney said the year “has proven to be a more challenging year than we initially expected,” prompting the company to guide for organic g...